HELP - Helus Pharma • Market Cap
Cybin Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel psychedelic-based therapeutics for various mental health conditions. Headquartered in Canada, the company's primary focus is on addressing unmet needs in areas such as depression, anxiety, and substance use disorders. Cybin employs a scientific approach to drug discovery and development, utilizing proprietary drug delivery systems and innovative compounds to create potentially safer and more effective treatments. Its pipeline includes several psychedelic-based molecules undergoing preclinical and clinical trials, with a strong emphasis on intellectual property protection and strategic partnerships to advance its research. The company aims to transform mental healthcare through the responsible and evidence-based application of psychedelic medicine.
854,8M
Market Cap
Market capitalization, or "market cap", is the aggregate market value of a company represented in a dollar amount. Since it represents the “market” value of a company, it is computed based on the current market price (CMP) of its shares and the total number of outstanding shares.
688,4M
EV
Enterprise value (EV) measures a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt and any cash or cash equivalents on the company's balance sheet.
0
EV/Revenue
The enterprise value-to-revenue multiple (EV/R) is a measure of the value of a stock that compares a company's enterprise value to its revenue. EV/R is one of several fundamental indicators that investors use to determine whether a stock is priced fairly. The EV/R multiple is also often used to determine a company's valuation in the case of a potential acquisition. It's also called the enterprise value-to-sales multiple.
-4,1
EV/EBITDA
The enterprise value to earnings before interest, taxes, depreciation, and amortization ratio (EV/EBITDA) compares the value of a company—debt included—to the company's cash earnings less non-cash expenses. It's best to use the EV/EBITDA metric when comparing companies within the same industry or sector. Typically, when evaluating a company, an EV/EBITDA value below 10 is seen as healthy.
-4,1
EV/EBIT
It follows the same logic as the EV/EBITDA indicator, but instead of EBITDA, EBIT is used, which considers non-cash D&A expenses in the company's operating result.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!